Novartis has reported decent Q2 results, with the lynchpin oncology franchise finally reviving. Also, continued strong growth in other major franchises like immunology, cardiovascular and neurology provided additional impetus. Moreover, the improvement in Sandoz’s prospects and upwards revision to the cost-saving targets despite tough external improvement was icing on the cake. Hence, our positive recommendation on the Swiss giant is reiterated.
20 Jul 2022
Decent Q2; clear growth momentum seen across key franchises
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Decent Q2; clear growth momentum seen across key franchises
Novartis has reported decent Q2 results, with the lynchpin oncology franchise finally reviving. Also, continued strong growth in other major franchises like immunology, cardiovascular and neurology provided additional impetus. Moreover, the improvement in Sandoz’s prospects and upwards revision to the cost-saving targets despite tough external improvement was icing on the cake. Hence, our positive recommendation on the Swiss giant is reiterated.